Dr. Cy Stein Sees a Role for Zytiga, Jevtana and Enzalutamide in Prostate Cancer

Cy Stein, M.D., Ph.D., an oncologist specializing in the biology and treatment of genitourinary cancers, discussed recent developments in prostate cancer with Elizabeth Krutoholow. The subtle differences between Johnson & Johnson’s Zytiga and Medivation’s enzalutamide could create a marketing battle.

Q: What is your standard approach for treating metastatic castrate resistant prostate cancer?

A: There is no standard approach and there are a lot of new agents in the pipeline. We only have one FDA approved drug-Dendreon’s Provenge.

Q: How would you describe your experience with Provenge?

A: I have used Provenge in the hospital setting, so I have not had any issues with reimbursement and I select patients that will not be turned down. There is a fear among community oncologists that they cannot lay out the money for Provenge. Hospitals can do well though

Bloomberg BRIEF Newsletters